Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene B Helenowski

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|April 22, 2008
Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin familyAndrew M Evens, Paul T Schumacker, Irene B Helenowski, et al.
JAMA|January 21, 2015
Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosisRichard K Burt, Roumen Balabanov, Xiaoqiang Han, et al.
European Burn Journal|January 21, 2026
The Role of Angiopoietin-2 in Post-Burn PneumoniaMary Grace Murray, Ryan M Johnson, Abigail B Plum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trialAndrew M Evens, William G Spies, Irene B Helenowski, et al.
Frontiers in Oncology|September 15, 2023
Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessmentYork E Miller, Moumita Ghosh, Daniel T Merrick, et al.
Journal of Cancer Research and Therapeutics|April 17, 2015
Atypical meningioma: randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapyHannah Yoon, Minesh P Mehta, Karthikeyan Perumal, et al.
Lancet (London, England)|February 1, 2013
Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysisRichard K Burt, Maria Carolina Oliveira, Sanjiv J Shah, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 7, 2012
Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trialSeema A Khan, Robert T Chatterton, Nancy Michel, et al.
American Journal of Hematology|February 12, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centersYasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, et al.
JAMA|January 16, 2019
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical TrialRichard K Burt, Roumen Balabanov, Joachim Burman, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|April 22, 2008
Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin familyAndrew M Evens, Paul T Schumacker, Irene B Helenowski, et al.
JAMA|January 21, 2015
Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosisRichard K Burt, Roumen Balabanov, Xiaoqiang Han, et al.
European Burn Journal|January 21, 2026
The Role of Angiopoietin-2 in Post-Burn PneumoniaMary Grace Murray, Ryan M Johnson, Abigail B Plum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trialAndrew M Evens, William G Spies, Irene B Helenowski, et al.
Frontiers in Oncology|September 15, 2023
Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessmentYork E Miller, Moumita Ghosh, Daniel T Merrick, et al.
Journal of Cancer Research and Therapeutics|April 17, 2015
Atypical meningioma: randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapyHannah Yoon, Minesh P Mehta, Karthikeyan Perumal, et al.
Lancet (London, England)|February 1, 2013
Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysisRichard K Burt, Maria Carolina Oliveira, Sanjiv J Shah, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 7, 2012
Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trialSeema A Khan, Robert T Chatterton, Nancy Michel, et al.
American Journal of Hematology|February 12, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centersYasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, et al.
JAMA|January 16, 2019
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical TrialRichard K Burt, Roumen Balabanov, Joachim Burman, et al.
Pageof 10